NaV1.7 Gain-of-Function Mutations as a Continuum: A1632E Displays Physiological Changes Associated with Erythromelalgia and Paroxysmal Extreme Pain Disorder Mutations and Produces Symptoms of Both Disorders


Introduction

It is now clear that there are nine different isoforms of voltage-gated sodium channels, all sharing a common overall motif but with distinct amino acid sequences and different physiological and pharmacological properties (Catterall et al., 2005). NaV1.7 sodium channels are unique in that they are preferentially expressed within primary sensory neurons of dorsal root (DRG) and trigeminal ganglion and sympathetic ganglion neurons (Felts et al., 1997; Sangameswaran et al., 1997; Toledo-Aral et al., 1997), especially within nociceptors (Djouhri et al., 2003), and display slow closed-state inactivation, a property that enables these channels to produce a depolarizing response to small slow depolarizations that are subthreshold with respect to the action potential (Cummins et al., 1998). The biophysical properties and subcellular distribution of NaV1.7 suggest that it functions to boost subthreshold stimuli, thereby setting the gain on nociceptors (Waxman, 2006; Rush et al., 2007).

Over the past few years, NaV1.7 has assumed a prominent role in pain research because mutations in this channel have been linked to inherited human pain syndromes (Dib-Hajj et al., 2007; Drenth and Waxman, 2007). Gain-of-function mutations (Yang et al., 2004; Dib-Hajj et al., 2005; Drenth et al., 2005; Michiels et al., 2005; Han et al., 2006; Lee et al., 2007) that shift activation of NaV1.7 in a hyperpolarizing direction, slow deactivation, and enhance ramp currents cause inherited erythromelalgia (IEE) (Cummins et al., 2004; Dib-Hajj et al., 2005; Choi et al., 2006; Han et al., 2006; Harty et al., 2006; Lampert et al., 2006; Sheets et
al., 2007; Cheng et al., 2008), a disorder in which patients experience severe burning pain in the feet and, in most cases, in the hands, in response to mild warmth and exercise. A different set of gain-of-function mutations that impair inactivation of Na\textsubscript{v}1.7 and in some cases produce a persistent current (Fertleman et al., 2006; Dib-Hajj et al., 2008; Jarecki et al., 2008) has been linked to a different, nonoverlapping syndrome, paroxysmal extreme pain disorder (PEPD), characterized by paroxysmal episodes of burning pain in the rectal, ocular, and mandibular areas accompanied by autonomic manifestations such as skin flushing (Fertleman et al., 2006). In contrast, loss-of-function mutations of Na\textsubscript{v}1.7 have been linked to congenital inability to experience pain (Cox et al., 2006; Ahmad et al., 2007; Goldberg et al., 2007).

In this paper, we describe and characterize a new mutation in Na\textsubscript{v}1.7, A1632E, in a patient with a unique mixed clinical phenotype that includes characteristics of both IEM and PEPD. We show that this mutation produces changes in channel function that have been previously observed separately in both IEM and PEPD, shifting activation in a hyperpolarizing direction, slowing deactivation, and enhancing ramp currents as reported previously for IEM mutations and also impairing inactivation as previously reported for PEPD mutations. We also show that this mutation produces hyperexcitability within both DRG and trigeminal ganglion neurons.

Materials and Methods

Patient. The patient is a Caucasian 10-year-old female with a life-long pain syndrome with characteristics of both IEM and PEPD. The subject and parents gave written informed consent, and the study was approved by the Ethics Committee of the Hollywood Memorial Hospital (Hollywood, FL).

Exon screening. Genomic DNA was purified from venous blood. Genomic DNA from 92 Caucasian individuals was used as a normal population control. Coding exons and flanking intronic sequences, as well as exons encoding S\textsuperscript{3} and S\textsuperscript{3} untranslated sequences within the cDNA were amplified and sequenced as described previously (Drenth et al., 2005). Genomic sequences were compared with the reference Na\textsubscript{v}1.7 cDNA (Klugbauer et al., 1995) to identify sequence variation.

Plasmid and stable cell line. The human Na\textsubscript{v}1.7 insert was cloned into a mammalian expression vector (Klugbauer et al., 1995) and converted to become TTX-R (hNa\textsubscript{v}1.7\textsubscript{R}) by Y362S substitution (Herzog et al., 2003). The A1632E mutation was introduced into hNa\textsubscript{v}1.7\textsubscript{R} using Quick-Change XL II site-directed mutagenesis (Stratagene). Transfected HEK 293 cells, grown under standard culture conditions (5% CO\textsubscript{2}, 37°C) in DMEM supplemented with 10% fetal bovine serum, were treated with G418 for several weeks and stable cell lines that express the mutant channel were selected. Cells for voltage-clamp recordings were sparsely subplated onto 35 mm culture dishes.

Primary sensory neuron isolation and transfection. Dorsal root ganglia and trigeminal ganglia from Sprague Dawley rat pups (postnatal day 1–5) were isolated and then cultured using the same protocol. Dissected ganglia were placed in ice-cold oxygenated complete saline solution (CSS), which contained the following (in mM): 137 NaCl, 5.3 KCl, 1 MgCl\textsubscript{2}, 25 sorbitol, 3 CaCl\textsubscript{2}, and 10 HEPES, pH 7.2. They were then transferred to an oxygenated, 37°C CSS solution containing 1.5 mg/ml Collagenase D (Roche Applied Science) and 0.6 mM EDTA, and incubated with gentle agitation at 37°C for 20 min. This solution was then exchanged with an oxygenated, 37°C CSS solution containing 1.5 mg/ml Collagenase A (Roche Applied Science), and 0.6 mM EDTA and 30 U/ml papain (Worthington Biochemicals) and was incubated with gentle agitation at 37°C for 20 min. The solution was then aspirated, and the ganglia triturated in DRG media [DMEM/F12 (1:1) with 100 U/ml penicillin, 0.1 mg/ml streptomycin (Invitrogen), and 10% fetal calf serum (Hyclone), which contained 1.5 mg/ml bovine serum albumin (Sigma-Aldrich) and 1.5 mg/ml trypsin inhibitor (Roche Applied Science)].

Either wild-type hNa\textsubscript{v}1.7\textsubscript{R} (WT) or hNa\textsubscript{v}1.7\textsubscript{R}–A1632E mutant channels were transiently transfected into the DRG or trigeminal ganglia neurons, along with enhanced green fluorescent protein (GFP), by electroporation with a Nucleofector II (Amaxa) using Rat Neuron Nucleofector Solution and program G-013. The ratio of sodium channel to GFP constructs was 5:1. The transfected neurons were allowed to recover for 5 min at 37°C in 0.5 mL of Ca\textsuperscript{2+}-free DMEM containing 10% fetal calf serum. The cell suspension was then diluted with DRG media containing 1.5 mg/ml bovine serum albumin and 1.5 mg/ml trypsin inhibitor, 80 μl was plated on 12 mm circular poly-γ-lysine/laminin precoated coverslips (BD Biosciences), and the cells were incubated at 37°C in 5% CO\textsubscript{2} for 30 min. DRG media (1 ml/well), supplemented with 50 ng/ml each of mouse NGF (Alomone Labs) and glial cell-derived neurotrophic factor (Peprotec), was then added, and the cells were maintained at 37°C in a 5% CO\textsubscript{2} incubator.

Electrophysiology. Whole-cell voltage-clamp recordings were performed using the following solutions. The extracellular solution contained the following (in mM): 140 NaCl, 3 KCl, 1 MgCl\textsubscript{2}, 1 CaCl\textsubscript{2}, and 10 HEPES, pH 7.3 with NaOH (adjusted to 320 mOsm with dextrose). The pipette solution contained the following (in mM): 135 Cs-aspartate, 10 NaCl, 2 MgCl\textsubscript{2}, 0.1 CaCl\textsubscript{2}, 1.1 EGTA, 0.6 Ca\textsubscript{2+}, and 10 HEPES, pH 7.2 with CsOH (adjusted to 310 mOsm with dextrose). Patch pipettes had a resistance of 1–3 MΩ when filled with pipette solution. The junction potential of 16 mV (calculated by pCalc included in pClamp software) was compensated by setting the holding potential during the seal test period to −16 mV. Once the seal had formed, these two solutions were no longer in contact and were applied separately. After achieving whole-cell recording configuration, the pipette and cell capacitance were manually minimized using the Axopatch 200B (Molecular Devices) compensation circuitry. To reduce voltage errors, 80–90% series resistance and prediction compensation was applied. Cells were excluded from analysis if the predicted voltage error exceeded 3 mV. The recorded currents were digitized using pClamp software (version 10) and a Digidata 1440A interface (Molecular Devices) at a rate of 50 kHz after passing through a low-pass Bessel filter setting of 10 kHz. Linear leak and residual capacitance artifacts were subtracted out using the P/N method provided by the Clampex software. Na-current recordings were initiated after a 5 min equilibration period once whole-cell configuration was achieved.

Data analysis was performed using Clampfit (Molecular Devices) or Origin (Microcal Software). To generate activation curves, cells were held at −100 mV and stepped to potentials of −80 to +40 mV in 5 mV increments for 100 ms. Peak inward currents obtained from activation protocols were converted to conductance values using the equation, $G = I/(V_{m} - E_{Na})$, for which $G$ is the conductance, $I$ is the peak inward current, $V_{m}$ is the membrane potential step used to elicit the response, and $E_{Na}$ is the reversal potential for sodium (determined for each cell using the x-axis intercept of a linear fit of the peak inward current response). Conductance data were normalized by the maximum conductance value and fit with a Boltzmann equation of the form $G = G_{\text{max}} + ((G_{\text{max}} - G_{\text{min}})/(1 + \exp(V_{m} - V_{1/2})/k))$, where $V_{1/2}$ is the midpoint of activation, and $k$ is a slope factor. To generate steady-state fast inactivation curves, cells were stepped to inactivating potentials of −170 to −30 mV for 500 ms followed by a 20 ms step to −20 mV. The protocol for slow inactivation consisted of a 30 s step to potentials varying from −120 to 10 mV, followed by a 100 ms step to −120 mV to remove fast inactivation and a 20 ms step to 0 mV to elicit a test response. Peak inward currents obtained from steady-state fast inactivation and slow inactivation protocols were normalized by the maximum current amplitude and fit with a Boltzmann equation of the form $I = I_{\text{max}} + (I_{\text{max}} - I_{\text{min}})/(1 + \exp(V_{m} - V_{1/2})/k))$, where $V_{1/2}$ represents the inactivating membrane potential, and $I_{\text{max}}$ represents the midpoint of inactivation.

Decaying currents were fit with a single-exponential equation of the form $I = A \cdot \exp(-t/\tau) + I_{r}$, where $A$ is the amplitude of the fit, $t$ is the time constant of decay, and $I_{r}$ is the asymptotic minimum to which the currents decay. Data are expressed as means ± SEM. Statistical significance was determined by Student’s t test.

Whole-cell current-clamp recordings were performed using the Axopatch 200B amplifier, digitized using the Digidata 1440A interface, and controlled using pClamp software. The bath solution for current-clamp
records containing the following (in mM): 140 NaCl, 3 KCl, 1 MgCl₂, 1 CaCl₂, and 10 HEPES, pH 7.3 with NaOH (adjusted to 315 mOsm with dextrose). The pipette solution contained the following (in mM): 140 KCl, 0.5 EGTA, 5 HEPES, and 3 Mg-ATP, pH 7.3 with KOH (adjusted to 300 mOsm with dextrose). The junction potential between these two solutions given by JPcalc was 5 mV, but no correction was applied for current-clamp experiments. Recordings were performed on transfected presumptive nociceptive neurons based on the morphology of small-diameter (20–28 μm) round cell bodies that also exhibited GFP fluorescence. All recordings were performed between 20 and 30 h after transfection. Coverslips were transferred to a perfusable chamber (Warner Instruments) and all recordings were initiated within 1 h. Whole-cell configuration was obtained in voltage-clamp mode before proceeding to the current-clamp recording mode. Cells with stable (<10% variation) resting membrane potentials (RMPs) more negative than −35 mV and overshooting action potentials (>85 mV RMP to peak) were used for additional data collection. Input resistance was determined by the slope of a line fit to hyperpolarizing responses to current steps of 10–35 pA. Threshold was determined by the first action potential elicited by a series of depolarizing current injections that increased in 5 pA increments. Action potential frequency was determined by quantifying the number of action potentials elicited in response to depolarizing current injections of 1 s duration.

Results

Clinical phenotype and identification of the A1632E mutation

The patient presented with apnea, bradycardia, and poor feeding since birth. Severe reflux, projectile vomiting, and a hypersensitive gag reflex required a fundoplication and gastrostomy tube for management. Bradycardic episodes, in which the patient would turn blue and sometimes required cardiopulmonary resuscitation, were precipitated by touching or stimulation such as eating, voiding, or bowel movements, and required insertion of a pacemaker at 18 months of age. Rectal sensitivity continued and episodes of periodic pain and erythema developed as the patient grew older. After age 3, the patient developed almost daily attacks of (1) unilateral eye, jaw, or facial discomfort and redness, (2) episodes of harlequin (half-face) redness and facial pain, (3) stomach pain, vomiting, or breath-holding spells, and (4) transient episodes of pain described as “hot needles” and erythema in the feet, hands, and head, often precipitated by warmth or being touched, and attenuated by cooling. The parents and a half sibling are asymptomatic.

Amplification and direct sequencing of all exons of SCN9A identified a heterozygous 4895C > A mutation in exon 26 in the index patient, which predicts amino acid substitution A1632E in NaV1.7. The mutation was not present in the unaffected father and mother, suggesting that this mutation appeared de novo. The 4895C > A mutation was absent in 92 unrelated healthy control subjects of the same ethnic origin. The A1632E mutation alters a highly conserved amino acid within the linker between transmembrane segments S4 and S5 in domain IV (Fig. 1). The amino acid sequence of this loop is highly conserved among all sodium membrane segments S4 and S5 of domain IV (Fig. 1). The amino acid sequence of this loop is highly conserved among all sodium membrane segments S4 and S5 of domain IV (Fig. 1). The amino acid sequence of this loop is highly conserved among all sodium membrane segments S4 and S5 of domain IV (Fig. 1).

Voltage-clamp recordings from HEK 293 cells stably expressing WT or A1632E mutant hNaV1.7R channels

Whole-cell voltage-clamp recordings were performed on clonal cell lines expressing either WT or A1632E channels. The activation properties of the currents expressed by these cells were tested by holding the cells at −100 mV and then applying 100 ms test pulses to potentials between −80 and +40 mV in 5 mV increments. Inward currents recorded by this protocol are shown for WT (Fig. 2A) and A1632E (Fig. 2B) channels. The average peak inward current was smaller for A1632E cells (0.95 ± 11 nA; n = 18) compared with WT cells (3.21 ± 0.41 nA; n = 9). This difference was maintained when normalized for capacitance to give a significant reduction in current density from the A1632E cells compared with WT cells (30.5 ± 3.8 pA/pF for A1632E; 152 ± 23 pA/pF for WT; p < 0.001). The amplitude of the current in HEK 293 cells transiently transfected with A1632E mutant channels was also smaller than that of HEK 293 cells transiently transfected with WT channels (data not shown), suggesting that the smaller current in the stable lines was not caused by the site of integration of the construct.

Time-to-peak and rate of deactivation

Examination of the mean time-to-peak (Fig. 2C) revealed a small increase in the time-to-peak for A1632E currents compared with WT currents, which was significant over the voltage range between −5 to +30 mV. An additional test for altered activation properties is to examine the deactivation kinetics as open channels transition back to the closed state. Single-exponential fits of the current decay (to measure time constant) showed that the A1632E channels close significantly more slowly over the entire voltage range from −100 to −40 mV (Fig. 2D).

Voltage dependence of activation and fast inactivation

The voltage dependence of activation and fast inactivation was examined by transforming the peak current versus voltage (I–V) curves into conductance versus voltage (G–V) curves as described in Materials and Methods. The G–V curve was fit to a Boltzmann function that directly gives the voltage midpoint (V₁/₂) as well as the slope factor (k) of the voltage-dependent response. The Boltzmann fits for both activation and fast inactivation were derived for each cell individually. The averages of the normalized G–V curves for activation and fast inactivation for both A1632E and WT channels are illustrated in Figure 2E. The average of the fits for fast inactivation revealed that, like other PEPD mutant Na channels, the V₁/₂ for A1632E channels was significantly shifted in the depolarizing direction compared with
WT (−63.9 ± 0.9 mV for A1632E, n = 18; −80.9 ± 1.4 mV for WT, n = 9; p < 0.001). In addition to this 17 mV shift in the depolarizing direction, the slope factor for A1632E fast inactivation became significantly steeper (5.61 ± 0.31 for A1632E; 8.13 ± 0.36 for WT; p < 0.001).

Comparing the average of the fits for the voltage dependence of activation revealed a shift, similar to the shift seen for other IEM mutations but not previously reported for PEPD mutations, of the midpoint of activation by the A1632E channels of 7 mV in the hyperpolarizing direction (−33.3 ± 0.6 mV for A1632E; −26.2 ± 1.6 mV for WT; p < 0.001).

Closer examination of the Boltzmann curves fitted to the averages for the A1632E displayed offsets from zero for both activation and inactivation (Fig. 2E). The offset from zero for activation was unexpected but was probably attributable to the low peak currents in A1632E-expressing cells, because the analysis finds peak inward currents and the offset represents actual currents of only 20–30 pA in reference to 1 nA I\textsubscript{\text{max}}, which was similar to bandwidth noise when using 10 kHz filtering. To display the window current predicted by the overlap of the activation and fast inactivation curves, the offset from zero determined from the fit of the activation G−V data were subtracted from both the activation and fast inactivation curves to account for the effect of small total I\textsubscript{\text{max}} values. Even after this correction, the offset from zero for A1632E fast inactivation appears to reflect an actual fraction of channels that failed to inactivate as demonstrated in Figure 4. The depolarizing shift of fast inactivation and the hyperpolarizing shift of activation for A1632E channels compared with WT channels results in a substantially increased predicted window current (Fig. 2F).

**Slow inactivation**

Inactivation of Na\textsubscript{v}1.7 channels occurs with at least two different time courses. In addition to the fast (10–100 ms) inactivation process, there is an additional inactivation process (slow inactivation) that develops over a much longer time frame (1–10 s). To determine whether the A1632E mutation altered the slow inactivation process, cells were held at a potential between −120 and 10 mV for 30 s to allow full development of both fast and slow inactivation. A 100 ms pulse to −120 mV was used to recover from fast inactivation, followed by a depolarizing pulse to 0 mV to activate the available channels. As illustrated in Figure 3A, the

---

**Figure 2.** A1632E shifts activation and fast inactivation. **A, B,** Typical data traces recorded from HEK cell lines expressing either the WT (A) or the hNa\textsubscript{v}1.7r–A1632E mutant (B) sodium channel. The current densities from the A1632E-expressing cell line were lower, with total peak inward currents averaging just under 1 nA. In comparison, the hNa\textsubscript{v}1.7r–WT clone total peak current averaged near 3 nA. For display purposes, the traces were digitally filtered to 2 kHz. **C,** The average time-to-peak for the traces recorded during the activation protocol are plotted as a function of test potential with the WT (n = 9) responses shown by open circles and the A1632E (AE) (n = 18) responses shown by filled circles. Error bars are ± SEM. **D,** Deactivation kinetics are derived from single-exponential fits to tail currents recorded in response to brief activating pulses (0 mV for 0.5 ms), followed by a repolarization to the indicated potential. Example data traces comparing the deactivation during repolarization to −50 mV are shown in the inset. The time constants are averaged and plotted with the WT (n = 9) and the A1632E (n = 7) shown by filled circles. Error bars are ± SEM. **E,** The peak inward currents elicited using either the activation or the fast-inactivation protocol were transformed into normalized conductance as described in Materials and Methods, and the average response at each test voltage was plotted using open symbols for WT (n = 9) and filled symbols for A1632E (n = 18). The activation data are plotted using circles and the fast-inactivation data are plotted using squares. Error bars are ± SEM. **F,** The predicted window current is larger for A1632E (solid lines) compared with WT (dashed lines).
Recovery from inactivation

Recovery from inactivation (repriming) occurs at different rates for specific channel subtypes, and the rate and extent of recovery is voltage dependent. This repriming of the channels was measured using a two-pulse protocol and varying the interpulse interval as well as the interpulse potential. The cell was first pulsed to 0 mV for 20 ms to allow complete fast inactivation and then repolarized to a specified potential for a range of durations to allow channel recovery, which is quantified as the ratio of the current evoked by the second pulse to 0 mV compared with the response to the first pulse. The rate and extent of recovery, comparing A1632E and WT channels for three different interpulse potentials, are shown in Figure 3B. At hyperpolarized interpulse potentials such as shown for −100 mV, the rate of recovery was rapid and was similar between A1632E and WT channels. For interpulse potentials of −80 and −60 mV, however, both the rate and the fraction of current recovered were larger for A1632E channels compared with WT channels.

Persistent currents

For both the fast inactivation and the slow inactivation protocols, the A1632E channels exhibited a fraction of channels resistant to inactivation. Non-inactivating channels could result in persistent sodium currents. The fraction of persistent current seen from A1632E-expressing cells was evaluated in two ways, by determining the offsets after fitting inactivation with an exponential function or by comparing the current that persists at 100 ms after onset of depolarization. The inactivation decay from A1632E cells, obtained by fitting with a single-exponential function, consistently needed an offset constant. The rate of fast inactivation as a function of stimulus pulse potential is shown in Figure 4A, which shows that the kinetics of A1632E channels are significantly slowed over the voltage range between −25 and +35 mV. Examples of traces showing the difference in inactivation between WT and A1632E currents and the persistent current at 100 ms are shown in Figure 4B–D. With pulses to −20 mV, which was near the voltage for peak current, the A1632E current decayed more slowly than WT and did not decay to zero. The same two traces at the end of the depolarization pulse are displayed at normalized by the amplitude of the response to the inactivation step and plotted as a function of recovery period duration. The averages for cells expressing WT channels (open symbols; n = 7) and A1632E channels (filled symbols; n = 8) are shown with error bars ± SEM. Single-exponential functions were fit to these averaged data and are shown by solid lines for A1632E and dashed lines for WT. C, This panel illustrates the responses to a ramp pulse protocol that spans the range of −100 to 20 mV over 600 ms (0.2 mV/ms). The response has been rescaled as the percentage of peak inward current recorded during the activation−I/V protocol. The peak currents from wild-type hNaV1.7 are much larger than from the A1632E-expressing cells, thus scaling the noise to be quieter. In addition, for display purposes, the WT trace has been post-acquisition filtered to 1 kHz, and the A1632E trace has been post-acquisition filtered to 500 Hz. The average peak ramp current from the A1632E cells was 4.2 ± 0.3% at −44.7 ± 0.7 mV (n = 12), whereas the peak ramp current from the WT cells averaged 0.77 ± 0.05% at −39.8 ± 0.7 mV (n = 9). Error bars are 1 SD.
higher gain in the inset, which clearly shows that the A1632E current has persisted for at least 100 ms (Fig. 4 B). With pulses to +15 mV, whereas the inactivation rate for WT channels has continued to speed up, the inactivation rate for A1632E channels appears to have leveled off (Fig. 4 C); the inset shows that, even at this potential, the A1632E current has persisted for at least 100 ms. If the A1632E channels exhibit persistent currents in the subthreshold range, this could contribute to neuronal hyperexcitability. Figure 4 D shows the response of WT and A1632E channels to a pulse to −50 mV, and once again the inset shows that A1632E current persists to at least 100 ms.

Quantification of the A1632E persistent current can be achieved by either fitting exponential functions or measuring the mean current for a 10 ms window near the end of the 100 ms activation pulse. Using either method, the peak persistent current averaged ~4% of the peak current from the I–V curve for each A1632E cell.

Ramp responses
We evaluated the response of WT and A1632E channels to small slow depolarizations using a slow ramp protocol that starts from a holding potential of −100 mV and steadily increases the applied potential to +20 mV over 600 ms for a ramp rate of 0.2 mV/ms. This slow rate fully inactivates many voltage-gated sodium channels, but NaV1.7 and many disease-causing NaV1.7 mutations still respond to this protocol. To compare between cells, the response is normalized to the peak inward current recorded during the activation I–V protocol. The response of the A1632E mutant compared with WT channels is shown in Figure 3 C. The peak of the slow ramp response of A1632E-expressing cells averaged 4.2%, which is a fivefold increase over the average ramp response of 0.77% in WT-expressing cells. In addition, the slow ramp response from A1632E-expressing cells typically showed a shoulder after the peak response that is consistent with a small fraction of channels persistently staying open.

Current-clamp recordings: DRG neurons
To assess the effect of the A1632E mutation on excitability, DRG neurons were transfected with either the WT or A1632E construct, and current-clamp recording conditions were used to determine RMP, action potential threshold, and firing frequency in small (22–28 μm) DRG neurons. The average size of the recorded DRG neurons was 25.4 ± 0.2 μm (n = 30) for WT-transfected and 25.3 ± 0.4 μm (n = 28) for A1632E-transfected cells. The RMP was −56.8 ± 1.1 mV for WT cells and was −54.2 ± 2.7 mV for A1632E cells. This small depolarization of A1632E RMP was not statistically significant. The input resistance was also similar between groups (719 ± 71 MΩ for WT; 695 ± 90 MΩ for A1632E). The main difference between these two groups was a reduction of current threshold for single action potentials for the A1632E-transfected cells (200 ± 36 pA for WT; 132 ± 22 pA for A1632E; p < 0.05).

The firing of action potentials of a representative DRG neuron transfected with either WT or A1632E is shown at threshold current stimuli (Fig. 5 A, B) and at current injections (1 s duration) near two and three times threshold as well as the current injection

![Figure 4](image-url)}
that elicited the maximal number of action potentials (Fig. 5C–H). At threshold, there was no difference in either the average action potential peak depolarization (58.8 ± 1.8 mV for WT; 54.6 ± 2.8 mV for A1632E) or the peak afterhyperpolarization (AHP) (–63 ± 1.6 mV for WT; –63 ± 1.5 mV for A1632E). Figure 5, C–E, shows representative WT-transfected DRG neurons that produce mostly single action potentials in response to a 1-s depolarization with an occasional second or third spike elicited by strong stimuli. A1632E-transfected DRG neurons, in contrast, commonly generated multiple action potentials. To compare the responses of DRG neurons transfected with either WT or A1632E sodium channels, the number of spikes elicited for current injections ranging from 50 to 500 pA in 50 pA steps were averaged together and plotted in Figure 6A. For each stimulus level, the A1632E-transfected DRG neurons responded with significantly more spikes compared with WT.

Current-clamp recording: trigeminal ganglion neurons

The A1632E mutation was found in a patient whose clinical phenotype includes pain in the periorcular and mandibular regions of the face. Because these areas are innervated by sensory neurons that reside in the trigeminal ganglion, we asked whether the A1632E mutation would induce hyperexcitability in those neurons. To assess the effect of the A1632E mutation on excitability, current-clamp recording was used to determine RMP, action potential threshold, and firing frequency in small (22–28 μm) rat trigeminal ganglion neurons that were transfected with either the WT or A1632E construct. The average size of the recorded trigeminal ganglion neurons was 23.8 ± 0.5 μm (n = 27) for WT-transfected cells and 24.4 ± 0.5 μm (n = 27) for A1632E. The RMP was –52.8 ± 1.5 mV for WT cells and –52.9 ± 1.5 mV for A1632E cells. The only significant difference was for input resistance (720 ± 102 MΩ for WT; 516 ± 26 MΩ for A1632E; p < 0.05). There was a trend toward reduction of current threshold for the A1632E-transfected cells (166 ± 21 pA for WT; 144 ± 24 pA for A1632E), but it did not reach statistical significance.

Similar to DRG neurons, representative trigeminal ganglion neurons transfected with either WT or A1632E channels are shown to illustrate the response at threshold (Fig. 7A,B) as well as the response to current injections near two and three times threshold and to stimuli eliciting the maximal response (Fig. 7C–H). At threshold, there was no difference in either the average action potential peak depolarization (55.2 ± 3.0 mV for WT; 55.8 ± 2.5 mV for A1632E) or the peak AHP (–58.2 ± 1.6 mV for WT; –59.9 ± 1.0 mV for A1632E). As shown in Figure 6B, trigeminal ganglion neurons transfected with A1632E responded with more spikes than neurons transfected with WT as measured at each stimulus level.

Discussion

In this study, we have identified a new mutation (A1632E) of the Naᵥ1.7 sodium channel in a patient with a painful disorder that includes clinical characteristics of both IEM and PEPD. Previously described IEM mutations all shift activation in a hyperpolarizing direction and slow deactivation, and many of these mutations enhance the Naᵥ1.7 ramp current (Dib-Hajj et al., 2007). Computer simulations suggest that the shift in activation is the largest contributor to DRG neuron hyperexcitability (Sheets et al., 2008). We show here that the A1632E mutation has a mixed...
physiological profile, with properties characteristic of both IEM and PEPD mutations. Using voltage-clamp recordings, we demonstrate that A1632E impairs fast inactivation, which is shifted 17 mV in a depolarizing direction, and slows fast inactivation, which is incomplete, resulting in persistent inward currents. We also demonstrate that A1632E produces a 7 mV hyperpolarizing shift in activation, slows deactivation, accelerates repriming, and increases the depolarizing response to slow ramp stimuli. Using current clamp, we demonstrate that A1632E increases the frequency of firing in response to suprathreshold stimuli, in both DRG and trigeminal ganglion neurons.

The length and sequence of the S4–S5 linker in domain IV, which carries the A1632E mutation, are highly conserved among most sodium channels described to date, suggesting an important role in normal channel function. Indeed, NaV1.4 channels with small insertions at two sites in this linker do not generate sodium currents (Mitrovic et al., 1996). Mutations in this linker have been identified in NaV1.1 from patients with severe myoclonic epilepsy of infancy (Claes et al., 2003; Nabbout et al., 2003), in NaV1.4 with diseases of skeletal muscle (Mitrovic et al., 1996; Fleischhauer et al., 1998; Rossignol et al., 2007; Schoser et al., 2007), and in NaV1.5 with cardiac disorders (Ruan et al., 2007). It is noteworthy that the A1632E mutation in NaV1.7 in this child with a chronic pain disorder is analogous to the A1481D mutation in NaV1.4 reported with cold-aggravated myotonia (Schoser et al., 2007). It remains to be seen whether the effects of A1481D on gating properties of NaV1.4 are similar to the effects of A1632E on NaV1.7.

The A1632E mutation is located within the DIV/S4–S5 linker, close to the PEPD mutation M1627K (Fertleman et al., 2006), suggesting a possible explanation for the effect of A1632E on NaV1.7 gating properties. Although a large shift of fast-inactivation voltage dependence is produced by both M1627K (Fertleman et al., 2006; Dib-Hajj et al., 2008) and A1632E (this study), the impairment of inactivation is smaller than with I1461T and T1464I PEPD mutations of the IFMT inactivation particle, which show a more substantial non-inactivating (persistent) inward current (Fertleman et al., 2006). Why the M1627K and A1632E mutations are better tolerated is not yet understood. The possibility that these mutations influence S4–S5 linker folding and therefore affect inactivation (Tang et al., 1996; Lerche et al., 1997; Smith and Goldin, 1997; McPhee et al., 1998) merits additional study.

An alanine residue is conserved at the site corresponding to A1632 in all sodium channels except NaV1.9, a channel characterized by hyperpolarized voltage dependence of activation and very slow inactivation, causing a persistent current (Cummins et al., 1999; Dib-Hajj et al., 1999), in which it is replaced by a serine (Fig. 1). It is possible that substitution of a serine for alanine in the DIV/S4–S5 linker contributes to these properties of NaV1.9. Surprisingly, a double mutation in NaV1.5 (P1655Q/A1656Q), which includes the site analogous to A1632 in NaV1.7, had no effect on the activation voltage dependence or the kinetics of inactivation but shifted inactivation in a hyperpolarized direction (Tang et al., 1998). However, it is difficult to assess the contribution of this residue to the gating properties of NaV1.5, because the single A1656Q mutation was not studied. A1632S substitution in NaV1.7, which recapitulates the sequence of this linker in NaV1.9, does not induce major shifts in activation or inactivation as seen with A1632E (data not shown). This suggests that a serine is better tolerated than a glutamate at this position. The mutant phenotype may be caused by the presence of a charge that destabilizes the inactivation complex, biasing the channel toward the activated/open state.

PEPD and IEM display distinct clinical phenotypes, with PEPD characterized by paroxysmal pain in a rectal, perioral, and perimandibular distribution, and IEM characterized by pain in the feet and, in most cases, the hands. Previously described PEPD mutations have been shown to impair inactivation and have not been reported to affect activation or deactivation (Fertleman et al., 2006; Jarecki et al., 2008). In contrast, mutations linked to IEM have been observed to hyperpolarize activation and slow deactivation, either without an effect on inactivation (Cummins et al., 2004; Choi et al., 2006; Lampert et al., 2006; Sheets et al., 2007; Cheng et al., 2008) or coupled to a shift in inactivation voltage dependence, which was, nevertheless, complete (Dib-Hajj et al., 2005; Han et al., 2006; Harty et al., 2006). The shifts of voltage dependence of activation and fast inactivation for these PEPD and IEM mutants are illustrated in Figure 8. The PEPD and IEM mutations characterized to date exhibit distinct nonoverlapping groupings of electrophysiological proper-
ties that correlate to and possibly predict their clinical phenotypes.

The A1632E mutation is associated with a mixed clinical phenotype that includes features of both PEPD (pain in perirectal, perimandibular, and periorbital areas) and erythromelalgia (pain in feet and hands). In parallel, A1632E exhibits a functional profile that includes electrophysiological properties characteristic of both PEPD and IEM (Fig. 8). As illustrated in this figure, comparison of the previously published IEM and PEPD mutations suggests that hyperpolarizing shifts in activation produce IEM, whereas depolarizing shifts in fast inactivation produce PEPD. The A1632E mutant provides evidence, in humans, that a Na<sub>v</sub>1.7 mutation causing both a hyperpolarizing shift in activation and a depolarizing shift in fast inactivation produces a clinical phenotype with characteristics of both disorders. The present results indicate that IEM and PEPD mutations are part of a physiological continuum that can produce a continuum of clinical phenotypes, including IEM, overlap disorders, and PEPD.

References


Figure 8. Comparison of IEM and PEPD mutations. The shifts in the voltage dependence of activation and fast inactivation of each mutant compared with wild-type hNaV1.7 are plotted with IEM mutants (open squares) and PEPD mutants (gray circles) numbered to identify the specific mutation and reference from which the data were compiled. The WT control is plotted as a black diamond at (0,0). The dotted lines through (0,0) demarcate between positive and negative shifts and indicate the outcome for the shifts. The A1632E mutation is plotted with the star symbol and shows shifts in activation and inactivation common to both IEM and PEPD mutants. The identity of each numbered symbol is as follows: 1, T1464I (Fertleman et al., 2006); 2, V1298F (Jarecki et al., 2008); 3, V1299F (Jarecki et al., 2008); 4, I1461T (Jarecki et al., 2008); 5, M1627K (Fertleman, 2006); 6, I1461T (Fertleman, 2006); 7, I136V (Cheng et al., 2008); 8, F1449V (Dib-Hajj, 2005); 9, A863P (Harty et al., 2006); 10, L858H (Cummins et al., 2004); 11, I848T (Cummins et al., 2004); 12, R964Q (Fertleman et al., 2006); 13, L858F (Han et al., 2006); 14, S241T (Lampert et al., 2006).